A Phase 1 Study of 68Ga-R11228 and 177Lu-R11228 in Breast Cancer

A phase 1 study of 68Ga-R11228 and 177Lu-R11228 in breast cancer.

Trial Details

NCT ID
NCT07121244
Phase
PHASE1
Sponsor
Radionetics Oncology
Status
RECRUITING
Cancer Type
ER/PR Positive (Hormone Receptor Positive) Breast Cancer
Interventions
  • 68Ga-R11228
  • 177Lu-R11228
Locations (sample)
  • Indianapolis, Indiana, United States|39.76838,-86.15804
  • Glen Burnie, Maryland, United States|39.16261,-76.62469
  • Princeton, New Jersey, United States|40.34872,-74.65905
  • Cleveland, Ohio, United States|41.4995,-81.69541
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • Pathologically confirmed estrogen and/or progesterone receptor (ER/PR) positive and HER2 negative locoregionally recurrent or metastatic breast cancer
  • At least one target or non-target lesion per RECIST v1.1 criteria.
  • Male or non-pregnant, non-lactating female subjects age ≥18 years.
  • Pathologically confirmed estrogen and/or progesterone receptor (ER/PR) positive and HER2 negative locoregionally recurrent or metastatic breast cancer

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find ER/PR Positive (Hormone Receptor Positive) Breast Cancer Trials on Trialify →